Table 2.
Assessment of sustainability: comparison between all of follow-up study with phases in the main trial (95% CI) of HHC identified and starting TPT at original intervention sites.
| HHC identified at intervention sites: | Compared to phase 1 (Difference in rates) | Compared to phase 2 (Difference in rates) |
|---|---|---|
| All countries (n = 8 sites)a | ||
| Phases 3&4 compared to: | 148 (−63, 359) | 10 (−84, 105) |
| LMIC only (n = 6 sites)a | ||
| Phases 3&4 compared to: | 208 (−50, 466) | 11 (−142, 164) |
|
HHC starting TPT at intervention sites: |
||
| All countries (n = 8 sites)b | ||
| Phases 3&4 compared to: | 35 (−10, 80) | −1 (−22, 20) |
| LMIC only (n = 6 sites)b | ||
| Phases 3&4 compared to | 44 (−37, 124) | −12 (−92, 69) |
Rates per 100 persons with pulmonary TB, in intervention sites (n = 8) and control sites in main trial) All countries (Benin, Canada, Ghana, and Indonesia) and in LMIC only (Benin, Ghana, Indonesia.
a
Estimated with marginal model with log link using NLESTIMATE, corrected for clustering.
b
Estimated with marginal model with log link using NLESTIMATE, corrected for clustering, and small clusters.